These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 22901566)

  • 1. Effectiveness of the combined evaluation of KLK3 genetics and free-to-total prostate specific antigen ratio for prostate cancer diagnosis.
    Zambon CF; Prayer-Galetti T; Basso D; Padoan A; Rossi E; Secco S; Pelloso M; Fogar P; Navaglia F; Moz S; Zattoni F; Plebani M
    J Urol; 2012 Oct; 188(4):1124-30. PubMed ID: 22901566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between KLK3 rs2735839 G/A polymorphism and serum PSA levels in Japanese men.
    Nobata S; Hishida A; Naito M; Asai Y; Mori A; Kuwabara M; Katase S; Okada R; Morita E; Kawai S; Hamajima N; Wakai K
    Urol Int; 2012; 89(1):39-44. PubMed ID: 22433834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prostate cancer susceptibility variant rs2735839 near KLK3 gene is associated with aggressive prostate cancer and can stratify gleason score 7 patients.
    He Y; Gu J; Strom S; Logothetis CJ; Kim J; Wu X
    Clin Cancer Res; 2014 Oct; 20(19):5133-5139. PubMed ID: 25274378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Search for genetic factor association with cancer-free prostate-specific antigen level elevation on the basis of a genome-wide association study in the Korean population.
    Choe EK; Lee Y; Cho JY; Choi SH; Park B; Lee JE; Cho EY
    Eur J Cancer Prev; 2018 Sep; 27(5):453-460. PubMed ID: 28471803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fine mapping the KLK3 locus on chromosome 19q13.33 associated with prostate cancer susceptibility and PSA levels.
    Parikh H; Wang Z; Pettigrew KA; Jia J; Daugherty S; Yeager M; Jacobs KB; Hutchinson A; Burdett L; Cullen M; Qi L; Boland J; Collins I; Albert TJ; Vatten LJ; Hveem K; Njølstad I; Cancel-Tassin G; Cussenot O; Valeri A; Virtamo J; Thun MJ; Feigelson HS; Diver WR; Chatterjee N; Thomas G; Albanes D; Chanock SJ; Hunter DJ; Hoover R; Hayes RB; Berndt SI; Sampson J; Amundadottir L
    Hum Genet; 2011 Jun; 129(6):675-85. PubMed ID: 21318478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kallikarein-related peptidase 3 common genetic variant and the risk of prostate cancer.
    Motamedi RK; Sarhangi N; Afshari M; Sattari M; Jamaldini SH; Samzadeh M; Mohsen Ziaei SA; Pourmand GR; Hasanzad M
    J Cell Biochem; 2019 Sep; 120(9):14822-14830. PubMed ID: 31017705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of KLK3 (PSA) genetic variants with prostate cancer risk and PSA levels.
    Penney KL; Schumacher FR; Kraft P; Mucci LA; Sesso HD; Ma J; Niu Y; Cheong JK; Hunter DJ; Stampfer MJ; Hsu SI
    Carcinogenesis; 2011 Jun; 32(6):853-9. PubMed ID: 21421545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of HNF1B, KLK3, ELAC2, TMPRSS2-ERG, and CTNNB1 polymorphisms associated with prostate cancer in samples of patients from HUPE-UERJ.
    Menezes RDS; Dornas MC; Campos CFF; Rodeiro DB; Carrerette FB; Oliveira RV; de Souza BA; Alves de Souza Carvalho G; Brito IAA; Silva DA; Damião R; Porto LC
    Prostate; 2024 Feb; 84(2):166-176. PubMed ID: 37839045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequency of KLK3 gene deletions in the general population.
    Rodriguez S; Al-Ghamdi OA; Guthrie PA; Shihab HA; McArdle W; Gaunt T; Alharbi KK; Day IN
    Ann Clin Biochem; 2017 Jul; 54(4):472-480. PubMed ID: 27555663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The association of 5-alpha reductase type 2 (SRD5A2) gene polymorphisms with prostate cancer in a Korean population.
    Choi SY; Kim HJ; Cheong HS; Myung SC
    Korean J Urol; 2015 Jan; 56(1):19-30. PubMed ID: 25598933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association study between common variations in some candidate genes and prostate adenocarcinoma predisposition through multi-stage approach in Iranian population.
    Beikzadeh B; Angaji SA; Abolhasani M
    BMC Med Genet; 2020 Apr; 21(1):81. PubMed ID: 32295536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of three assays for total serum prostate-specific antigen and percentage of free prostate-specific antigen in predicting prostate histology.
    Roehrborn CG; Gregory A; McConnell JD; Sagalowsky AI; Wians FH
    Urology; 1996 Dec; 48(6A Suppl):23-32. PubMed ID: 8973696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial.
    Catalona WJ; Partin AW; Slawin KM; Brawer MK; Flanigan RC; Patel A; Richie JP; deKernion JB; Walsh PC; Scardino PT; Lange PH; Subong EN; Parson RE; Gasior GH; Loveland KG; Southwick PC
    JAMA; 1998 May; 279(19):1542-7. PubMed ID: 9605898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic correction of PSA values using sequence variants associated with PSA levels.
    Gudmundsson J; Besenbacher S; Sulem P; Gudbjartsson DF; Olafsson I; Arinbjarnarson S; Agnarsson BA; Benediktsdottir KR; Isaksson HJ; Kostic JP; Gudjonsson SA; Stacey SN; Gylfason A; Sigurdsson A; Holm H; Bjornsdottir US; Eyjolfsson GI; Navarrete S; Fuertes F; Garcia-Prats MD; Polo E; Checherita IA; Jinga M; Badea P; Aben KK; Schalken JA; van Oort IM; Sweep FC; Helfand BT; Davis M; Donovan JL; Hamdy FC; Kristjansson K; Gulcher JR; Masson G; Kong A; Catalona WJ; Mayordomo JI; Geirsson G; Einarsson GV; Barkardottir RB; Jonsson E; Jinga V; Mates D; Kiemeney LA; Neal DE; Thorsteinsdottir U; Rafnar T; Stefansson K
    Sci Transl Med; 2010 Dec; 2(62):62ra92. PubMed ID: 21160077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of gene polymorphisms of KLK3 and prostate cancer: A meta-analysis.
    Li H; Fei X; Shen Y; Wu Z
    Adv Clin Exp Med; 2020 Aug; 29(8):1001-1009. PubMed ID: 32869960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kallikrein 3 and vitamin D receptor polymorphisms: potentials environmental risk factors for prostate cancer.
    Hu J; Qiu Z; Zhang L; Cui F
    Diagn Pathol; 2014 Apr; 9():84. PubMed ID: 24755043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between three genetic variants in kallikrein 3 and prostate cancer risk.
    Ding WH; Ren KW; Yue C; Zou JG; Zuo L; Zhang LF; Bai Y; Okada A; Yasui T; Mi YY
    Biosci Rep; 2018 Dec; 38(6):. PubMed ID: 30413614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL.
    Kwiatkowski MK; Recker F; Piironen T; Pettersson K; Otto T; Wernli M; Tscholl R
    Urology; 1998 Sep; 52(3):360-5. PubMed ID: 9730444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Age-Specific Cutoff Value for the Application of Percent Free Prostate-Specific Antigen (PSA) in Chinese Men with Serum PSA Levels of 4.0-10.0 ng/ml.
    Chen R; Huang Y; Cai X; Xie L; He D; Zhou L; Xu C; Gao X; Ren S; Wang F; Ma L; Wei Q; Yin C; Tian Y; Sun Z; Fu Q; Ding Q; Zheng J; Ye Z; Ye D; Xu D; Hou J; Xu K; Yuan J; Gao X; Liu C; Pan T; Sun Y;
    PLoS One; 2015; 10(6):e0130308. PubMed ID: 26091007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variants in the prostate-specific antigen (PSA) gene and prostate cancer risk, survival, and circulating PSA.
    Severi G; Hayes VM; Neufing P; Padilla EJ; Tilley WD; Eggleton SA; Morris HA; English DR; Southey MC; Hopper JL; Sutherland RL; Boyle P; Giles GG
    Cancer Epidemiol Biomarkers Prev; 2006 Jun; 15(6):1142-7. PubMed ID: 16775173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.